Drug Research

The pharmaceutical industry faces persistent challenges in the transition of drug candidates from discovery to clinical application. A primary obstacle is the accurate prediction of how a formulation will perform within the complex biological environment of the human body....

Pharmaceutical giant Bristol Myers Squibb has announced the deployment of its second NVIDIA DGX SuperPOD, an advanced computing cluster designed to accelerate the drug discovery pipeline. This new infrastructure, which utilizes the Vera Rubin architecture, represents a significant commitment...

The pharmaceutical sector is currently witnessing a profound shift in the methodology used to identify new chemical and biological entities. For decades, the discovery process relied heavily on high-throughput screening, where millions of existing molecules were tested against a...

The pharmaceutical industry is currently facing a critical challenge in the management of safety risks associated with new drug candidates. For decades, the high rate of attrition during late-stage clinical trials has been a primary driver of the rising...

The pharmaceutical industry is currently facing a period of intense structural adjustment as the costs associated with bringing a new therapy to market continue to rise. For decades, the industry has operated under a model where the average cost...

The pharmaceutical industry has long struggled with the immense complexity of conditions affecting the central nervous system. For decades, the high failure rate in clinical trials for Alzheimer's and Parkinson's disease has been a source of frustration for researchers...

The global oncology sector is currently undergoing a significant shift as the complexity of the disease continues to outpace traditional research methods. For decades, the search for effective treatments was defined by a broad approach that often failed to...